Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

@inproceedings{Ou2011CrizotinibAN,
  title={Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond},
  author={S H Ignatius Ou},
  booktitle={Drug design, development and therapy},
  year={2011}
}
Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR mutations were subsequently discovered in 2004, and heralded the era of molecular targeted therapy in NSCLC. The discovery of anaplastic lymphoma kinase (ALK) rearrangement in NSCLC in 2007 by two independent groups not only represents the first time ALK rearrangement has been discovered in common solid tumors but also… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
63 Citations
62 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 62 references

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients

  • W Tan, KD Wilner, Y Bang
  • J Clin Oncol
  • 2010
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…